Deepa J. Jeyakumar
Hematology | Oncology
101 The City Drive South
Building 23
Orange, CA 92868
Building 23
Orange, CA 92868
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 41 publications
The PRIME trial: An investigator-initiated, multicentre, phase II study of the poly(ADP-ribose) polymerase inhibitor olaparib in isocitrate dehydrogenase (IDH)-mutated relapsed/refractory acute myeloid leukaemia and myelodysplastic syndromes.
Journal: British journal of haematology
Published: July 02, 2026
Prominence-guided link prediction in fuzzy robotic networks.
Journal: Scientific reports
Published: October 14, 2025
Venetoclax combined with cladribine, idarubicin, cytarabine (CLIA-VEN) results in higher remission rates over conventional 7 + 3 chemotherapy without increased toxicity in newly diagnosed acute myeloid leukaemia.
Journal: British journal of haematology
Published: August 28, 2025
Unfavorable disease progression in patients with chronic myeloid leukemia and concurrent t(6;9) translocation (DEK::NUP214 fusion) or inversion 16 (CBFB::MYH11 fusion).
Journal: Cancer genetics
Published: June 23, 2025
Adequate Catchment Area Representation in Cancer Clinical Trials at NCI Designated Cancer Centers: The University of California Irvine Experience.
Journal: Cancer medicine
Published: June 18, 2025
CLO25-058: First-in-Human, Multicenter Phase 1 Study of the Bromodomain 2 Inhibitor ABBV-744 in Relapsed/Refractory Acute Myeloid Leukemia.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 28, 2025
A phase 1 trial of ibrutinib and azacitidine for higher risk myelodysplastic syndromes (University of California Hematologic Malignancies Consortium Study 1503).
Journal: Leukemia research
Published: March 18, 2025
Narsoplimab for refractory transplantation-associated thrombotic microangiopathy (TA-TMA) in adult patients receiving allogeneic hematopoietic stem cell transplantation (AHSCT).
Journal: Bone marrow transplantation
Published: January 17, 2025
CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myelogenous leukemia: a University of California Hematologic Malignancies Consortium trial.
Journal: Leukemia & lymphoma
Published: December 17, 2024
Intensification of upfront chemotherapy for patients with myeloid blast phase CML: a single center experience.
Journal: Annals of hematology
Published: September 08, 2024
Last Updated: 09/26/2026